YW2036(CAS No.:2131223-92-0) is a promising small molecule inhibitor with ability to selectively target protein kinases, particularly PKC

YW2036 (CAS No.:2131223-92-0) is a novel small molecule inhibitor that has gained widespread attention due to its ability to selectively target specific protein kinases. This compound has been shown to have potent inhibitory activity against protein kinase C (PKC), which is a key regulator of many intracellular signaling pathways.

The mechanism of action of YW2036 involves the binding of this inhibitor to the ATP-binding site of PKC, thereby preventing its activation and subsequent downstream signaling pathways. In doing so, YW2036 has shown to be highly effective in reducing inflammation and inhibiting cell proliferation, making it a promising therapeutic agent for a variety of pathological disorders.

Studies have demonstrated that YW2036 exhibits a range of biological activities, including antitumor, antiviral, and anti-inflammatory effects. This compound has been shown to inhibit the growth of cancer cells in vitro and in vivo, and to prevent the replication of viruses such as hepatitis C and HIV. Furthermore, YW2036 has also been shown to have an analgesic effect, making it a potential therapeutic agent for the treatment of chronic pain.

In conclusion, YW2036 is a promising small molecule inhibitor with a variety of potential clinical applications. Its ability to selectively target protein kinases, particularly PKC, has shown to be highly effective in inhibiting various pathological processes. As such, YW2036 represents an exciting new avenue for drug discovery and development.

References:

1. Lee H, et al. A novel small molecule inhibitor of protein kinase C delta (PKCδ) reduces inflammatory pain via blockade of the ERK1/2 pathway. Molecular Pain. 2017;13:1744806917697016.

2. Qu L, et al. Discovery of a novel PKC inhibitor (YW2036) with potent antiviral activity by high-throughput screening. Journal of Biomolecular Screening. 2013;18(10):1140-1149.

3. Zhang W, et al. A novel protein kinase C inhibitor, YW2036, inhibits the growth of human gastric cancer cells in vitro and in vivo. Anti-Cancer Drugs. 2014;25(3):301-308.